The Medicines (NASDAQ:MDCO) Receives Coverage Optimism Score of 0.13
News coverage about The Medicines (NASDAQ:MDCO) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. The Medicines earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news coverage about the company an impact score of 46.5656009706123 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- The Medicines’ (MDCO) “Buy” Rating Reiterated at Cowen and Company (campdesrecrues.com)
- The Medicines Company (NASDAQ:MDCO) Stock Rating Lowered by TheStreet (vothemes.com)
- The Medicines Company (NASDAQ:MDCO) Receives $56.86 Average Price Target from Analysts (famososartistas.com)
- The Medicines Company (MDCO) Stake Increased by Alliancebernstein LP (ismboard.com)
- The Medicines Company (MDCO) Stake Up in Latest Report from Alliancebernstein LP (overnewsmagazine.com)
A number of brokerages have recently commented on MDCO. Cowen and Company reaffirmed a “buy” rating and set a $54.00 price target (down previously from $61.00) on shares of The Medicines in a research report on Thursday. Jefferies Group LLC reaffirmed a “buy” rating and set a $54.00 price target (down previously from $62.00) on shares of The Medicines in a research report on Thursday. TheStreet lowered The Medicines from a “c-” rating to a “d” rating in a research note on Wednesday. Zacks Investment Research upgraded The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price objective on the stock in a research note on Tuesday. Finally, Citigroup Inc. boosted their price objective on The Medicines from $43.00 to $45.00 and gave the company a “neutral” rating in a research note on Wednesday, July 26th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The Medicines presently has an average rating of “Buy” and an average price target of $52.36.
The Medicines (NASDAQ MDCO) traded up 4.18% during mid-day trading on Friday, hitting $37.40. The company had a trading volume of 1,564,687 shares. The Medicines has a 52 week low of $30.80 and a 52 week high of $55.95. The company’s market capitalization is $2.69 billion. The firm’s 50 day moving average is $37.99 and its 200 day moving average is $44.48.
The Medicines (NASDAQ:MDCO) last announced its quarterly earnings data on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.29) by $4.23. The Medicines had a negative net margin of 670.46% and a negative return on equity of 137.20%. The business had revenue of $18.74 million during the quarter, compared to analysts’ expectations of $29.64 million. During the same quarter in the previous year, the firm earned ($0.62) earnings per share. The Medicines’s revenue was down 65.8% on a year-over-year basis. On average, equities research analysts predict that The Medicines will post ($5.98) EPS for the current year.
The Medicines Company Profile
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.